MedTrace Logo

AK112 and Cadonilimab Combined With Chemotherapy for 1L Treatment of Metastatic Pancreatic Cancer

NCT06646055 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 110

Last updated 2026-03-09

No results posted yet for this study

Summary

This trial is a Phase Ib/II study. All patients are stage IV pancreatic cancer (PDAC) patients with Eastern Cooperative Oncology Group (ECOG) performance status of 0-1. The purpose of this study is to evaluate the safety and efficacy of AK112 and Cadonilimab combined with chemotherapy as first-line treatment for patients with metastatic pancreatic cancer.

Conditions

Interventions

DRUG

AK112, Cadonilimab, nab-paclitaxel, gemcitabine

IV infusion, specified dose on specified days.

DRUG

AK112, Cadonilimab, nab-paclitaxel, gemcitabine

IV infusion, specified dose on specified days.

DRUG

AK112, Cadonilimab, nab-paclitaxel, gemcitabine

IV infusion, specified dose on specified days.

DRUG

AK112, nab-paclitaxel, gemcitabine

IV infusion, specified dose on specified days.

DRUG

nab-paclitaxel, gemcitabine

IV infusion, specified dose on specified days.

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-01-21
Primary Completion
2026-12-30
Completion
2027-12-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06646055 on ClinicalTrials.gov